Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Akeso's Il-17A Monoclonal Antibody (Gumokimab) Completion Of Patient Enrollment In Phase II Clinical Trial For The Treatment Of Ankylosing Spondylitis

prnasiaDecember 29, 2021

Tag: Akeso , Gumokimab , Ankylosing Spondylitis

PharmaSources Customer Service